Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of FDA Peptide Reclassification 2026: What Researchers Want FDA Peptide Update: Category 2 Removals Explained FDA's Overreach on Compounded Peptides Peptide power laws Chief Longevity Officer